BioScrip Inc. (NASDAQ:BIOS) Director R Carter Pate acquired 20,000 shares of the stock in a transaction that occurred on Thursday, November 10th. The shares were bought at an average price of $1.30 per share, with a total value of $26,000.00. Following the completion of the purchase, the director now owns 84,000 shares in the company, valued at $109,200. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

BioScrip Inc. (NASDAQ:BIOS) opened at 1.39 on Wednesday. The firm’s market cap is $163.58 million. BioScrip Inc. has a 12 month low of $1.15 and a 12 month high of $3.43. The firm’s 50-day moving average price is $2.69 and its 200-day moving average price is $2.66.

BioScrip (NASDAQ:BIOS) last announced its quarterly earnings data on Monday, November 7th. The company reported ($0.12) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.05) by $0.07. The business earned $224.50 million during the quarter, compared to the consensus estimate of $223.26 million. During the same period in the prior year, the company earned ($0.38) EPS. The company’s revenue for the quarter was down 9.2% on a year-over-year basis. Equities research analysts predict that BioScrip Inc. will post ($0.39) earnings per share for the current year.

Several hedge funds have recently made changes to their positions in BIOS. Ardsley Advisory Partners purchased a new stake in shares of BioScrip during the third quarter worth approximately $12,521,000. Coliseum Capital Management LLC increased its stake in shares of BioScrip by 295.3% in the second quarter. Coliseum Capital Management LLC now owns 5,622,410 shares of the company’s stock worth $14,337,000 after buying an additional 4,200,000 shares in the last quarter. Deerfield Management Co. purchased a new stake in shares of BioScrip during the second quarter worth approximately $7,616,000. Gabelli Funds LLC increased its stake in shares of BioScrip by 23.8% in the second quarter. Gabelli Funds LLC now owns 14,483,253 shares of the company’s stock worth $36,932,000 after buying an additional 2,785,536 shares in the last quarter. Finally, First Light Asset Management LLC increased its stake in shares of BioScrip by 592.5% in the second quarter. First Light Asset Management LLC now owns 2,092,082 shares of the company’s stock worth $5,335,000 after buying an additional 1,789,972 shares in the last quarter. Institutional investors own 85.85% of the company’s stock.

A number of research analysts have issued reports on BIOS shares. Zacks Investment Research lowered BioScrip from a “buy” rating to a “hold” rating in a research report on Friday, August 12th. Jefferies Group started coverage on BioScrip in a research report on Tuesday, November 8th. They set a “buy” rating and a $2.50 price target for the company.

About BioScrip

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

5 Day Chart for NASDAQ:BIOS

Receive News & Stock Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related stocks with our FREE daily email newsletter.